PA SB804

Prohibits the manufacture, sale, or distribution of intravenous solution containers (IV bags) made with intentionally added DEHP beginning January 1, 2030, with a possible extension to January 1, 2032 for manufacturers awaiting FDA approval or lacking adequate equipment

Bans intravenous tubing made with intentionally added DEHP beginning January 1, 2035

Prohibits replacing DEHP with any other ortho-phthalate in new or revised medical devices, and limits unintentionally added DEHP to below 0.1% weight per weight

Exempts human blood collection and storage bags, as well as apheresis and cell therapy blood kits and bags (including integral tubing) from the prohibitions

Cites legislative findings that DEHP is classified by the EPA as a probable human carcinogen and an endocrine-disrupting compound linked to reproductive harm, liver and kidney damage, and potential multidrug resistance in breast cancer treatment